Growth in the primary cells market is mainly driven by factors such as increasing cancer research, the advantages of primary human cells over cell lines, the increasing demand for monoclonal antibodies, rapid growth in the biotechnology biopharmaceutical industries, and growing focus on personalized medicine. Biomedical research using primary cells in 3D cultures is also expected to provide a wide range of growth opportunities for players in the market. On the other hand, concerns regarding primary cell culture contamination are expected to limit market growth to a certain extent in the coming years.

Download PDF Brochure: @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=32854960

Primary Cell Market

The global primary cells market size is projected to reach USD 1,613 million by 2025 from USD 970 million in 2020, at a CAGR of 10.7% during the forecast period.

The human primary cells segment accounted for the largest share of the primary cells market, by origin segment, in 2019

Based on origin, the primary cells market is segmented into human and animal primary cells. The human primary cells segment accounted for the largest share in the primary cells market in 2019. The growing application areas of human stem cells and the rising incidence of cancer are the major factors driving the growth of this segment.

Hepatocytes segment to register the highest growth rate during the forecast period

Based on type, the primary cells market is segmented into hematopoietic cells, dermatocytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and other primary cells. In 2019, the hepatocytes segment accounted for the highest growth rate. This can be attributed to the increasing incidence of liver cancer pediatric liver diseases across the globe, increasing research funding by key pharma players, and the emergence of new companies dedicated to liver therapeutics research.

The life science research companies segment accounted for the largest share of the primary cells market, by end user segment, in 2019

Based on end-users, the primary cells market is segmented into life science research companies and research institutes. In 2019, the life science research companies segment for the largest share in the primary cells market. Increasing cancer research in life science research companies, the increasing number of RD facilities, high adoption of primary cells in cell-based experiments, and the increasing investments of companies in cell-based research are the major factors driving the growth of this segment.

North America is the largest regional market for primary cells market

The primary cells market is segmented into four major regions, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW). In 2019, North America accounted for the largest share in the primary cells market. The growth in the North American primary cells market can be attributed to increasing funding for cancer research, growing life science research sector, expansion of the healthcare sector, and the high adoption of stem cell therapy cell immunotherapies for the treatment of cancer and chronic diseases.

The major players operating in this market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Lonza (Switzerland), Cell Biologics, Inc. (US), PromoCell GmbH (Germany), HemaCare Corporation (US), ZenBio, Inc. (US), STEMCELL Technologies, Inc. (Canada), Corning Incorporated (US), AllCells (US), American Type Culture Collection (US), Axol Bioscience Ltd. (UK), iXCells Biotechnologies (US), Neuromics (US), StemExpress (US), BioIVT (US), ScienCell Research Laboratories, Inc. (US), PPA Research Group, Inc. (US), Creative Bioarray (US), BPS Bioscience, Inc. (US), Epithelix Sàrl (Switzerland), ReachBio LLC (US), AcceGen (US), Sekisui XenoTech, LLC (US), and Biopredic International (France).

Thermo Fisher Scientific accounted for the largest share of the primary cells market in 2019. The company maintains its leading position in the primary cells market due to its well-established product portfolio. The company adopted partnerships and expansions as key strategies to strengthen its position as well as expand its product portfolio. Thermo Fisher Scientific will be investing more than USD 475 million in new capabilities at its St. Louis site (Missouri, US) to expand its biological development manufacturing, cell gene therapy, and drug product development capacity. Such developments have helped the company enhance its visibility in the primary cells market.

Access Sample Copy of the Report @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=32854960

Don't miss out on business opportunities in Primary Cells Market. Speak to our analyst and gain crucial industry insights that will help your business grow.